Shanghai Xianbo Biotech Co., Ltd, known as Simnova outside of China and an affiliate of Simcere Investment Group, has received tacit clinical trial approval from Chinese authorities for its SNC109, an in-house developed treatment for recurrent glioblastoma.
SNC109 is a dual chimeric antigen receptor (CAR)-T cell therapy designed on Xianbo Bio’s CAR-T platform, targeting IL13Rα2 and HER2, with initial development focused on treating glioblastoma. This CAR-T therapy also has the capability to secrete multi-specific antibodies (BiTE) targeting EGFR and EGFRvIII. The BiTE molecule, composed of two nanoantibodies (VHH) and a single chain variable fragment (scFv), can activate endogenous T cells to exert cytotoxic effects through flexible fusion junctions connected in series.
In addition to SNC109, the company’s universal allogeneic CD19 CAR-NK cell injection has earned tacit trial approvals for the treatment of non-Hodgkin’s lymphoma (NHL) and B-cell acute leukemia (ALL) in July and August of this year, respectively. A clinical filing for the use of this therapy in moderate to severe refractory systemic lupus erythematosus is currently under review in China.- Flcube.com
